{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:38:57Z","timestamp":1774525137821,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.canlet.2013.03.030","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T12:13:17Z","timestamp":1364904797000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors"],"prefix":"10.1016","volume":"338","author":[{"given":"Holly A.","family":"Porter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhan L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achsah D.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2010","key":"10.1016\/j.canlet.2013.03.030_b0005","first-page":"2893","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN","volume":"127","author":"Ferlay","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.03.030_b0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/0253-7613.81497","article-title":"Promising molecular targeted therapies in breast cancer","volume":"43","author":"Munagala","year":"2011","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.canlet.2013.03.030_b0015","unstructured":"Breast cancer, A.D.A.M, 1993. <http:\/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/000913.htm#Definition> (Accessed 23.02.12)."},{"key":"10.1016\/j.canlet.2013.03.030_b0020","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1158\/0008-5472.CAN-08-2524","article-title":"Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1","volume":"69","author":"Wang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0167-5699(97)80019-9","article-title":"The Th1\/Th2 paradigm","volume":"18","author":"Romagnani","year":"1997","journal-title":"Immunol. Today"},{"key":"10.1016\/j.canlet.2013.03.030_b0030","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.4049\/jimmunol.172.9.5467","article-title":"IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins","volume":"172","author":"Conticello","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2013.03.030_b0035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/sj.cdd.4402305","article-title":"Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4","volume":"15","author":"Todaro","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2013.03.030_b0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/cmi.2009.53","article-title":"Paradoxical roles of IL-4 in tumor immunity","volume":"6","author":"Li","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2013.03.030_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cyto.2008.01.016","article-title":"IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells","volume":"42","author":"Zhang","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.canlet.2013.03.030_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1006806722619","article-title":"The IRS-signalling system: a network of docking proteins that mediate insulin action","volume":"182","author":"White","year":"1998","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.canlet.2013.03.030_b0055","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1128\/MCB.17.3.1513","article-title":"Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells","volume":"17","author":"Bruning","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.03.030_b0060","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1210\/endo.141.6.7584","article-title":"Perspective: the insulin signaling system\u2013a common link in the pathogenesis of type 2 diabetes","volume":"141","author":"Withers","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2013.03.030_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cr.1998.1","article-title":"Regulation of gene expression, growth, and cell survival by IL-4: contribution of multiple signaling pathways","volume":"8","author":"Keegan","year":"1998","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0070","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signalling and the regulation of glucose and lipid metabolism","volume":"414","author":"Saltiel","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2013.03.030_b0075","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/sj.bjc.6603354","article-title":"Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells","volume":"95","author":"Byron","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2013.03.030_b0080","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1128\/MCB.01032-06","article-title":"Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis","volume":"26","author":"Ma","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.03.030_b0085","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1128\/MCB.21.15.5082-5093.2001","article-title":"Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion","volume":"21","author":"Shaw","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.03.030_b0090","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1128\/MCB.24.22.9726-9735.2004","article-title":"Involvement of insulin receptor substrate 2 in mammary tumor metastasis","volume":"24","author":"Nagle","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.03.030_b0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1478-811X-7-14","article-title":"Expression and function of the insulin receptor substrate proteins in cancer","volume":"7","author":"Mardilovich","year":"2009","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2013.03.030_b0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4161\/cc.6.6.3987","article-title":"Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis","volume":"6","author":"Gibson","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2013.03.030_b0105","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1038\/sj.onc.1204920","article-title":"Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines","volume":"20","author":"Jackson","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.03.030_b0110","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1158\/0008-5472.CAN-05-2858","article-title":"Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase\/activator protein-1 signaling to regulate cell migration","volume":"66","author":"Cui","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/B:BREA.0000010709.31256.c6","article-title":"Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression","volume":"83","author":"Zhang","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2013.03.030_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2012.04.020","article-title":"Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death","author":"Porter","year":"2012","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1541-7786.MCR-08-0005","article-title":"The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity","volume":"6","author":"Willis","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ncb2080","article-title":"Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression","volume":"12","author":"Teo","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2013.03.030_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2012.03.026","article-title":"Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion","author":"Whitsett","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2013.03.030_b0140","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1541-7786.MCR-09-0194","article-title":"Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function","volume":"7","author":"Fortin","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F","article-title":"Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer","volume":"89","author":"Schnarr","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.03.030_b0295","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-011-1353-1","article-title":"Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer","author":"Clark","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2013.03.030_b0155","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jcp.2006.039107","article-title":"Expression of nuclear insulin receptor substrate 1 in breast cancer","volume":"60","author":"Sisci","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.canlet.2013.03.030_b0160","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1074\/jbc.275.17.12565","article-title":"Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line","volume":"275","author":"Molloy","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2013.03.030_b0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2249.1994.tb06029.x","article-title":"Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells","volume":"95","author":"Obiri","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2013.03.030_b0170","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1158\/1078-0432.CCR-11-1808","article-title":"Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation","volume":"18","author":"Burt","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0175","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1074\/jbc.273.16.9994","article-title":"Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells","volume":"273","author":"Jackson","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2013.03.030_b0180","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1158\/0008-5472.CAN-09-1224","article-title":"Overexpression of kinesins mediates docetaxel resistance in breast cancer cells","volume":"69","author":"De","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0185","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1074\/jbc.274.12.8208","article-title":"Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells","volume":"274","author":"Wang","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2013.03.030_b0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1568011053352569","article-title":"Targeting microtubules for cancer chemotherapy","volume":"5","author":"Zhou","year":"2005","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.canlet.2013.03.030_b0195","first-page":"2891","article-title":"Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells","volume":"36","author":"Momparler","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CAD.0b013e328012a9a0","article-title":"Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin","volume":"18","author":"Koehn","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canlet.2013.03.030_b0205","first-page":"986","article-title":"Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis","volume":"47","author":"Beere","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2013.03.030_b0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cyto.a.21172","article-title":"Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin\/topotecan, mitoxantrone, or etoposide","volume":"81","author":"Zhao","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.canlet.2013.03.030_b0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0300-9084(84)90018-X","article-title":"Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review","volume":"66","author":"Aubel-Sadron","year":"1984","journal-title":"Biochimie"},{"key":"10.1016\/j.canlet.2013.03.030_b0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2013.03.030_b0225","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/1097-0142(19800215)45:4<735::AID-CNCR2820450421>3.0.CO;2-S","article-title":"Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial","volume":"45","author":"Glick","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2013.03.030_b0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/cc.6.6.4035","article-title":"Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2","volume":"6","author":"Dearth","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2013.03.030_b0235","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1038\/sj.onc.1206803","article-title":"Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2","volume":"22","author":"Cui","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.03.030_b0240","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/mend.13.3.0256","article-title":"Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene","volume":"13","author":"Vassen","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2013.03.030_b0245","first-page":"103","article-title":"Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival","volume":"3","author":"Rocha","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0250","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/jcp.2004.022590","article-title":"Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases","volume":"58","author":"Koda","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.canlet.2013.03.030_b0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.biochi.2004.10.019","article-title":"Positive and negative regulation of insulin signaling through IRS-1 phosphorylation","volume":"87","author":"Gual","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.canlet.2013.03.030_b0260","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJM197806012982203","article-title":"The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer","volume":"298","author":"Lippman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2013.03.030_b0265","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM197812142992403","article-title":"Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer","volume":"299","author":"Kiang","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2013.03.030_b0270","first-page":"1429","article-title":"Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation","volume":"1","author":"Surmacz","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0275","first-page":"2606","article-title":"Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells","volume":"57","author":"Guvakova","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.03.030_b0280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<299::AID-IJC21>3.0.CO;2-8","article-title":"Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells","volume":"81","author":"Salerno","year":"1999","journal-title":"Int. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513002723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513002723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T13:34:03Z","timestamp":1562852043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513002723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0304383513002723"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.03.030","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}